ELSEVIER

Drug and Alchol Dependence 41 (1996) 221

DRUG and ALCOHOL DEPENDENCE

# Author index

## Volume 42 (1996)

Acteo, M.D. **42**, 93
Alborch, E. **42**, 65
Allan Klock, P. **42**, 197
Anglin, M.D. **42**, 183
Ann Chutuape, M. **42**, 117
Apfelbaum, J.L. **42**, 133, 197
Archer, L.D. **42**, 39
Aye, K.W. **42**, 105

Barberá, M.D. **42**, 65
Batumalail, S. **42**, 105
Bauer, L.O. **42**, 21
Benjamin Bowser **42**, 85
Besteman, K.J. **42**, 125
Bonieskie, L.M. **42**, 77
Booth, R.E. **42**, 11
Bowman, E. **42**, 93
Brady, J.V. **42**, 125
Brooner, R.K. **42**, 117
Brown, J. **42**, 49
Butelman, E. **42**, 93

Childress, A.R. **42**, 167
Coalson, D.W. **42**, 197
Cornish, J.W. **42**, 167
Craft, R.M. **42**, 27
Crowley, T.J. **42**, 11

Dawson, D.A. **42**, 39
de Miguel, R. **42**, 155
De Smet, A. **42**, 125
Dodds, L.D. **42**, 77
Doyle, J.M. **42**, 143
Dudish, S.A. **42**, 55

Edlin, B.R. **42**, 85
Ehrman, R.N. **42**, 167
English, J.A. **42**, 93

Faruque, S. **42**, 85
Fernàndez-Ruiz, J.J. **42**, 155
Festinger, D.S. **42**, 77

García, L. **42**, 155
Glass, D.J. **42**, 77
Grant, B.F. **42**, 39
Greenfield, L. **42**, 125

Harris, L. **42**, 93
Hatsukami, D.K. **42**, 55
HIV Infection Study Team, T.M.C.C. **42**, 85
Holmberg, S.D. **42**, 85
Husband, S.D. **42**, 77

Inciardi, J. **42**, 85
Irwin, K.L. **42**, 85
Isralowitz, R.E. **42**, 147

Jacobson, A.E. **42**, 93
Jordan, N. **42**, 197
Jover, T. **42**, 65

Kidorf, M. **42**, 117
King, V.L. **42**, 117
Kirby, K.C. **42**, 77
Klafta, J.M. **42**, 197
Klock, P.A. **42**, 133

Latkin, C.A. **42**, 175
Leo, G.I. **42**, 49
Longshore, D. **42**, 183
Low, W.Y. **42**, 105

Mandell, W. **42**, 175
Marks, S. **42**, 133, 197
Marlowe, D.B. **42**, 77
Mattson, M.V. **42**, 93
McKay, M.A. **42**, 133
Medzihradsky, F. **42**, 93
Moss, H.B. **42**, 1
Mott, A.E. **42**, 21
Mucha, R.F. **42**, 209
Mutz, G. **42**, 209

Neale, M.C. **42**, 1

O'Brien, C.P. **42**, 167
Ortí, M. **42**, 65

Patrick, G. **42**, 93
Pauli, P. **42**, 209
Peleg, A. **42**, 147
Platt, J.J. **42**, 77

Ramos, J.A. **42**, 155
Robbins, S.J. **42**, 167
Rowlett, J.K. **42**, 93

Salom, J.B. **42**, 65
Science, E. **42**, 73
Serrano, Y. **42**, 85
Smith, C.B. **42**, 93
Sobell, L.C. **42**, 49
Sobell, M.B. **42**, 49
Stein, J.A. **42**, 183
Stephan, E. **42**, 209
Stitzer, M.L. **42**, 117
Stratmann, J.A. **42**, 27

Tarter, R.E. **42**, 1
Thomas, H. **42**, 201
Toledano, A.Y. **42**, 133, 197
Torregrosa, G. **42**, 65

Vanyukov, M.M. **42**, 1
Virginia McCoy, H. **42**, 85
Vlahov, D. **42**, 175

Winger, G. **42**, 93
Woods, J.H. **42**, 93
Woolverton, W.L. **42**, 93
Word, C. **42**, 85

Young, C.J. **42**, 133, 197
Yusof, K. **42**, 105

Zacny, J.P. **42**, 133, 197
Zhang, Y. **42**, 11
Zulkifli, S.N. **42**, 105

ELSEVIER

Drug and Alcohol Dependence 41 (1996) 223–225

DRUG and ALCOHOL DEPENDENCE

# Subject index

## Volume 42 (1996)

**Abuse**; Nitrous oxide; Reinforcer; Choice; Subjective; Human; General anesthetic **42**, 197

**Abuse potential**; Zipeprol; Opioid abuse; Piperazine **42**, 93

**Acquired immunodeficiency syndrome**; Injection drug users; Human immunodeficiency virus; Alcohol consumption; Alcohol abuse; Crack cocaine; Social networks; Peer influence **42**, 175

**Adolescents**; Drug abuse; Knowledge; Attitudes; Perception; Parents; Malaysia **42**, 105

**Adverse effects**; Cannabis; Community survey; Cannabis and psychosis **42**, 201

**Alcohol abuse**; Acquired immunodeficiency syndrome; Injection drug users; Human immunodeficiency virus; Alcohol consumption; Crack cocaine; Social networks; Peer influence **42**, 175

**Alcohol abusers**; Self-reports; Drinking reliability; Timeline Follow-back **42**, 49

**Alcohol consumption**; Acquired immunodeficiency syndrome; Injection drug users; Human immunodeficiency virus; Alcohol abuse; Crack cocaine; Social networks; Peer influence **42**, 175

**Alcohol**; Evoked Potentials; EEG; Cocaine; Nicotine **42**, 21

**Alcohol**; Social network; Students **42**, 147

**Amphetamine**; Cannabinoids; $\Delta^9$-tetrahydrocannabinol; Midbrain dopaminergic neurons; Dopamine; Tyrosine hydroxylase; $D_1$ and $D_2$ receptors; Motor behavior; SCH 23390; Sulpiride; NSD 1015 **42**, 155

**Analgesia**; Fentanyl; Opioid; Opiate; Reinforcer; Subjective; Pain; Human; Volunteer **42**, 133

**Assortative mating**; Social homogamy; Contagion; Heritability **42**, 1

**Attitudes**; Drug abuse; Knowledge; Perception; Parents; Adolescents; Malaysia **42**, 105

**$Ca^{2+}$ channel**; Cocaine; Cerebral arteries; Human; Goat **42**, 65

**Cannabinoids**; $\Delta^9$-tetrahydrocannabinol; Midbrain dopaminergic neurons; Dopamine; Tyrosine hydroxylase; $D_1$ and $D_2$ receptors; Motor behavior; SCH 23390; Sulpiride; Amphetamine; NSD 1015 **42**, 155

**Cannabis and psychosis**; Cannabis; Community survey; Adverse effects **42**, 201

**Cannabis**; Community survey; Adverse effects; Cannabis and psychosis **42**, 201

**Cerebral arteries**; Cocaine; Human; Goat; $Ca^{2+}$ channel **42**, 65

**Choice**; Nitrous oxide; Reinforcer; Subjective; Human; General anesthetic; Abuse **42**, 197

**Cocaine**; Cerebral arteries; Human; Goat; $Ca^{2+}$ channel **42**, 65

**Cocaine**; Crack; Epidemiology; Gender differences **42**, 55

**Cocaine**; Drug discrimination; Sex differences **42**, 27

**Cocaine**; Evoked Potentials; EEG; Alcohol; Nicotine **42**, 21

**Cocaine**; Psychosis; Ritanserin **42**, 167

**Community survey**; Cannabis; Adverse effects; Cannabis and psychosis **42**, 201

**Contagion**; Assortative mating; Social homogamy; Heritability **42**, 1

**Crack cocaine**; Acquired immunodeficiency syndrome; Injection drug users; Human immunodeficiency virus; Alcohol consumption; Alcohol abuse; Social networks; Peer influence **42**, 175

**Crack**; Cocaine; Epidemiology; Gender differences **42**, 55

**Crack cocaine**; Substance abuse, intravenous; HIV infection **42**, 85

**$D_1$ and $D_2$ receptors**; Cannabinoids; $\Delta^9$-tetrahydrocannabinol; Midbrain dopaminergic neurons; Dopamine; Tyrosine hydroxylase; Motor behavior; SCH 23390; Sulpiride; Amphetamine; NSD 1015 **42**, 155

**Diagnostic validity**; Opioid abuse; Methadone treatment; Substance use diagnoses **42**, 117

**Dopamine**; Cannabinoids; $\Delta^9$-tetrahydrocannabinol; Midbrain dopaminergic neurons; Tyrosine hydroxylase; $D_1$ and $D_2$ receptors; Motor behavior; SCH 23390; Sulpiride; Amphetamine; NSD 1015 **42**, 155

**Drinking reliability**; Self-reports; Alcohol abusers; Timeline Follow-back **42**, 49

**Drug abuse**; Knowledge; Attitudes; Perception; Parents; Adolescents; Malaysia **42**, 105

**Drug discrimination**; Cocaine; Sex differences **42**, 27

**Drug use**; HIV; IDU; Treatment **42**, 11

**EEG**; Evoked Potentials; Cocaine; Alcohol; Nicotine **42**, 21

**Epidemiology**; Cocaine; Crack; Gender differences **42**, 55

**Ethnicity**; Injection drug use; HIV risk reduction **42**, 183

**Evoked Potentials**; EEG; Cocaine; Alcohol; Nicotine **42**, 21

**Fentanyl**; Opioid; Opiate; Reinforcer; Subjective; Analgesia; Pain; Human; Volunteer **42**, 133

**Gender differences**; Cocaine; Crack; Epidemiology **42**, 55

**General anesthetic**; Nitrous oxide; Reinforcer; Choice; Subjective; Human; Abuse **42**, 197

**Goat**; Cocaine; Cerebral arteries; Human; $Ca^{2+}$ channel **42**, 65

**Heart rate**; Smokers; Situational specifity; Tolerance; Natural environment **42**, 209

**Heritability**; Assortative mating; Social homogamy; Contagion **42**, 1

**HIV**; IDU; Drug use; Treatment **42**, 11

**HIV infection**; Crack cocaine; Substance abuse, intravenous **42**, 85

**HIV risk reduction**; Injection drug use; Ethnicity **42**, 183

**Human**; Cocaine; Cerebral arteries; Goat; $Ca^{2+}$ channel **42**, 65

**Human**; Fentanyl; Opioid; Opiate; Reinforcer; Subjective; Analgesia; Pain; Volunteer **42**, 133

**Human immunodeficiency virus**; Acquired immunodeficiency syndrome; Injection drug users; Alcohol consumption; Alcohol abuse; Crack cocaine; Social networks; Peer influence **42**, 175

**Human**; Nitrous oxide; Reinforcer; Choice; Subjective; General anesthetic; Abuse **42**, 197

**IDU**; HIV; Drug use; Treatment **42**, 11

**Injection drug use**; HIV risk reduction; Ethnicity **42**, 183

**Injection drug users**; Acquired immunodeficiency syndrome; Human immunodeficiency virus; Alcohol consumption; Alcohol abuse; Crack cocaine; Social networks; Peer influence **42**, 175

**Knowledge**; Drug abuse; Attitudes; Perception; Parents; Adolescents; Malaysia **42**, 105

**Malaysia**; Drug abuse; Knowledge; Attitudes; Perception; Parents; Adolescents **42**, 105

**Methadone**; Patient retention; Mobile health services **42**, 125

**Methadone treatment**; Diagnostic validity; Opioid abuse; Substance use diagnoses **42**, 117

**Midbrain dopaminergic neurons**; Cannabinoids; $\Delta^9$-tetrahydrocannabinol; Dopamine; Tyrosine hydroxylase; $D_1$ and $D_2$ receptors; Motor behavior; SCH 23390; Sulpiride; Amphetamine; NSD 1015 **42**, 155

**Mobile health services**; Patient retention; Methadone **42**, 125

**Motor behavior**; Cannabinoids; $\Delta^9$-tetrahydrocannabinol; Midbrain dopaminergic neurons; Dopamine; Tyrosine hydroxylase; $D_1$ and $D_2$ receptors; SCH 23390; Sulpiride; Amphetamine; NSD 1015 **42**, 155

**Natural environment**; Smokers; Situational specifity; Heart rate; Tolerance **42**, 209

**Nicotine**; Evoked Potentials; EEG; Cocaine; Alcohol **42**, 21

**Nitrous oxide**; Reinforcer; Choice; Subjective; Human; General anesthetic; Abuse **42**, 197

**NSD 1015**; Cannabinoids; $\Delta^9$-tetrahydrocannabinol; Midbrain dopaminergic neurons; Dopamine; Tyrosine hydroxylase; $D_1$ and $D_2$ receptors; Motor behavior; SCH 23390; Sulpiride; Amphetamine **42**, 155

**Opiate**; Fentanyl; Opioid; Reinforcer; Subjective; Analgesia; Pain; Human; Volunteer **42**, 133

**Opioid abuse**; Diagnostic validity; Methadone treatment; Substance use diagnoses **42**, 117

**Opioid abuse**; Zipeprol; Abuse potential; Piperazine **42**, 93

**Opioid**; Fentanyl; Opiate; Reinforcer; Subjective; Analgesia; Pain; Human; Volunteer **42**, 133

**Pain**; Fentanyl; Opioid; Opiate; Reinforcer; Subjective; Analgesia; Human; Volunteer **42**, 133

**Parents**; Drug abuse; Knowledge; Attitudes; Perception; Adolescents; Malaysia **42**, 105

**Patient retention**; Methadone; Mobile health services **42**, 125

**Peer influence**; Acquired immunodeficiency syndrome; Injection drug users; Human immunodeficiency virus; Alcohol consumption; Alcohol abuse; Crack cocaine; Social networks **42**, 175

**Perception**; Drug abuse; Knowledge; Attitudes; Parents; Adolescents; Malaysia **42**, 105

**Piperazine**; Zipeprol; Abuse potential; Opioid abuse **42**, 93

**Psychosis**; Cocaine; Ritanserin **42**, 167

**Reinforcer**; Fentanyl; Opioid; Opiate; Subjective; Analgesia; Pain; Human; Volunteer **42**, 133

**Reinforcer**; Nitrous oxide; Choice; Subjective; Human; General anesthetic; Abuse **42**, 197

**Ritanserin**; Cocaine; Psychosis **42**, 167

**SCH 23390**; Cannabinoids; $\Delta^9$-tetrahydrocannabinol; Midbrain dopaminergic neurons; Dopamine; Tyrosine hydroxylase; $D_1$ and $D_2$ receptors; Motor behavior; Sulpiride; Amphetamine; NSD 1015 **42**, 155

**Self-reports**; Alcohol abusers; Drinking reliability; Timeline Followback **42**, 49

**Sex differences**; Drug discrimination; Cocaine **42**, 27

**Situational specifity**; Smokers; Heart rate; Tolerance; Natural environment **42**, 209

**Smokers**; Situational specifity; Heart rate; Tolerance; Natural environment **42**, 209

**Social homogamy**; Assortative mating; Contagion; Heritability **42**, 1

**Social network**; Alcohol; Students **42**, 147

**Social networks**; Acquired immunodeficiency syndrome; Injection drug users; Human immunodeficiency virus; Alcohol consumption; Alcohol abuse; Crack cocaine; Peer influence **42**, 175

**Students**; Alcohol; Social network **42**, 147

**Subjective**; Fentanyl; Opioid; Opiate; Reinforcer; Analgesia; Pain; Human; Volunteer **42**, 133

**Subjective**; Nitrous oxide; Reinforcer; Choice; Human; General anesthetic; Abuse **42**, 197

**Substance abuse, intravenous**; Crack cocaine; HIV infection **42**, 85

**Substance use diagnoses**; Diagnostic validity; Opioid abuse; Methadone treatment **42**, 117

**Sulpiride**; Cannabinoids; $\Delta^9$-tetrahydrocannabinol; Midbrain dopaminergic neurons; Dopamine; Tyrosine hydroxylase; $D_1$ and $D_2$ receptors; Motor behavior; SCH 23390; Amphetamine; NSD 1015 **42**, 155

**$\Delta^9$-tetrahydrocannabinol**; Cannabinoids; Midbrain dopaminergic neurons; Dopamine; Tyrosine hydroxylase; $D_1$ and $D_2$ receptors; Motor behavior; SCH 23390; Sulpiride; Amphetamine; NSD 1015 **42**, 155

**Timeline Followback**; Self-reports; Alcohol abusers; Drinking reliability **42**, 49

**Tolerance**; Smokers; Situational specifity; Heart rate; Natural environment **42**, 209

**Treatment**; HIV; IDU; Drug use **42**, 11

**Tyrosine hydroxylase**; Cannabinoids; $\Delta^9$-tetrahydrocannabinol; Midbrain dopaminergic neurons; Dopamine; $D_1$ and $D_2$ receptors; Motor behavior; SCH 23390; Sulpiride; Amphetamine; NSD 1015 **42**, 155

**Volunteer**; Fentanyl; Opioid; Opiate; Reinforcer; Subjective; Analgesia; Pain; Human **42**, 133

**Zipeprol**; Abuse potential; Opioid abuse; Piperazine **42**, 93